SCHEMBL15769866

SCHEMBL15769866

CN(C)c1cnc(Nc2ccc(C3CC3)c(C#N)c2)nc1N(C)[C@H]1CCCN2CCCC[C@H]12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 5/20 0.36
CCNT1 O60563 3/20 0.36
CCNA2 P20248 3/20 0.36
CDK2 P24941 3/20 0.36
CDK9 P50750 3/20 0.36
CCNB1 P14635 2/20 0.36
CDK7 P50613 2/20 0.36
CCNH P51946 2/20 0.36
PIK3CD O00329 1/20 0.36
PRKAB2 O43741 1/20 0.36
NUAK1 O60285 1/20 0.36
ABL1 P00519 1/20 0.36
FYN P06241 1/20 0.36
CSF1R P07333 1/20 0.36
RET P07949 1/20 0.36
PDGFRB P09619 1/20 0.36
FGFR1 P11362 1/20 0.36
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCNE1 P24864 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15769976 0.93 CDK1 (0.39) CDK1CCNT1CCNA2CDK2CDK9
SCHEMBL15769468 0.91 JAK3 (0.45) CDK1CCNT1CCNA2CDK2CDK9
SCHEMBL15769287 0.90 GRM5 (0.38) CDK1CCNT1CCNA2CDK2CDK9
SCHEMBL15769778 0.90 JAK2 (0.39) CDK1CCNT1CCNA2CDK2CDK9
SCHEMBL15769875 0.90 JAK2 (0.39) CDK1CCNT1CCNA2CDK2CDK9
SCHEMBL15770094 0.90 JAK3 (0.38) CDK1CCNT1CCNA2CDK2CDK9
SCHEMBL15769905 0.89 CDK1 (0.40) CDK1CDK2CCNB1NUAK1CDK4
SCHEMBL15769485 0.89 JAK3 (0.49) JAK3LCKKCNH2
SCHEMBL15769944 0.86 LRRK2 (0.31)
SCHEMBL15769449 0.86 SYK (0.42) CDK1CDK2CDK4JAK3MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP claimed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US claimed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US claimed
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP disclosed
US-9913843-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-03-13 US disclosed
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2015-10-29 US disclosed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB CDK1 389/4885CCNT1 3618/4885CCNA2 2336/4885
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB CDK1 389/4885CCNT1 3618/4885CCNA2 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.